足拓的

基本解释 (translations)

volar

与足拓的相关的网络例句 [注：此内容来源于网络，仅供参考]

The HE stained slides of transplanted tumors showed that the cells presented sarcomatoid carcinoma morphology.

用MTT的方法检测该细胞系对顺铂、阿霉素、足叶乙甙、拓扑替康四种化疗药物的敏感性。

Meta-analyses showed that the response rate of TP (topotecan + cisplatin) regimen had no significant difference compared with EP regimen (etoposide + cisplatin) with OR 0.83 and 95%CI 0.63 to 1.09, but myelo-suppression such as leucopenia and thrombopenia was more severe with TP regimen; the response rate of monotherapy with topotecan was similar with that of CE (carboplatin + etoposide) regimen with OR 0.59 and 95%CI 0.22 to 1.60; the response rate of TEP (topotecan + etoposide + cisplatin) regimen was comparable with that of EP regimen with OR 1.37 and 95%CI 0.82 to –2.28, but myelosuppression and anemia were more severe with TEP regimen; the response rate with OR 0.97 and 95％CI 0.60 to –1.57, median time to progression with WMD –2.32 and 95％CI –5.72 to 1.09 and median survival time with WMD –1.65 and 95％CI –7.13 to 3.83 of IV topotecan were similar to those of oral topotecan, while neutropenia was more severe with IV topotecan.

Meta分析结果表明，TP 方案与EP方案的反应率相似 [OR 0.83， 95%CI (0.63，1.09)]，但具有相对高的致血小板下降的骨髓毒性；单药拓朴替康与CE方案的反应率相似 [OR 0.59， 95%CI (0.22，1.60)]；TEP方案（拓扑替康＋足叶乙甙＋顺铂）与EP方案的反应率相似 [OR 1.37， 95%CI (0.82，2.28)]，TEP方案致化疗后重度白细胞下降、重度血小板下降、重度血红蛋白下降均高于EP方案；口服拓扑替康与静脉滴注拓扑替康的化疗后反应率 [OR 0.97， 95％CI (0.60，1.57)]、中位疾病进展期 [WMD –2.32， 95％CI (–5.72， 1.09)]、中位生存期 [WMD –1.65， 95％CI (–7.13，3.83)] 相似，口服拓扑替康化疗后重度中性粒细胞下降明显低于静脉滴注拓扑替康。

Injection of rhIL-2 (200,100,50,25,12. 5 ku/kg) can inhibit mouse ear swelling, especially when dosage is 25～50 ku/kg. Injection of rhIL-2 (25 ku/kg) can inhibit rat plantar swelling. The function of mononuclear macrophage system was strengthened by hypodermic injection of rhIL-2( 100 ku/kg) once a day for 9 days. The decrease of mouse delayed-type hypersensitivity reaction induced by cyclophosphamide was extenuated by hypodermic injection of rhIL-2(50 ku/kg) once a day for 6 days. IL-2 has anti-inflammatory effects and immunomodulatory effects when administered in certain dosage.

RhIL-2注射液，剂量为20，10，5，2.5，1.25万u/kg时，对小鼠鼠耳肿胀模型有抑制作用，其中剂量为2.5～5万u/kg时，抑制率最大；剂量为2.5万u/kg时，对大鼠足拓肿胀模型有显著的抑制作用；rhIL-2注射液每日sc用药剂量为10万u/kg，连续给药9d后，可以明显增强小鼠单核吞噬细胞功能；rhIL-2注射液每日sc用药剂量为5万u/kg，连续给药6d后，可明显减轻由免疫抑制剂引起的小鼠迟发性变态反应降低的强度。rhIL-2在一定剂量范围内可以起到抗炎和免疫调节作用。

Mouse ear swelling and rat plantar swelling were used as animal models of anti-inflammatory efficacy. Immunomodulatory effects were studied by carbon clearunce and delayed hypersensitivity reaction in mice.

选择小鼠鼠耳肿胀和大鼠足拓肿胀模型研究rhIL-2的抗炎作用；选择碳廓清率实验、迟发性变态反应实验研究rhIL-2的免疫调节作用。